The Role of Radiotherapy in Patients with Refractory Hodgkin Lymphoma after Brentuximab Vedotin and -/or Immune Checkpoint Inhibitors

被引：0

作者：

Liu, Ting-Bo ^{[1
]}

Li, Xiaofan ^{[2
]}

Zhao, Rui-Zhi ^{[1
]}

Shao, Han ^{[3
]}

Shi, Gui-Qing ^{[1
]}

Qiu, Yan-Yan ^{[1
]}

Tang, Tian-Lan ^{[1
]}

Lin, Yu-Ping ^{[1
]}

Chen, Si-Lin ^{[1
]}

Huang, Cheng ^{[1
]}

Liao, Si-Qin ^{[1
]}

Chen, Jin-Hua ^{[1
]}

Fu, Hai-Ying ^{[4
]}

Liu, Jian-Zhi ^{[1
]}

Shen, Jian-Zhen ^{[1
]}

Xu, Ben-Hua ^{[1
]}

Zhang, Yu-jing ^{[3
]}

Yang, Yong ^{[1
]}

机构：

[1] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China

[2] Fujian Med Univ, Union Clin Med Coll, Fuzhou, Peoples R China

[3] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China

[4] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp 3, Fuzhou, Peoples R China

来源：

关键词：

Radiotherapy; Hodgkin lymphoma; Brentuximab vedotin; Immune; checkpoint inhibitors; Refractory; Relapse;

D O I：

10.1182/blood-2023-184773

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：2